[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345166-105":59,"doc-detail-345166-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","diagnostic-accuracy-in-brafv600e-negative-papillary-thyroid-cancer-via-5-gene-expression-profiling-of-residual-nucleic-acids-from-mutation-testing-a-retrospective-study","Diagnostic accuracy in BRAFV600E-negative papillary thyroid cancer via 5-gene expression profiling of residual nucleic acids from mutation testing - a retrospective study","","BRAFV600E mutation is widely used in clinical practice, yet it is insufficient for accurate diagnosis of thyroid neoplasms. This retrospective study aimed to build an mRNA-based model to identify thyroid cancer in indeterminate thyroid nodules when BRAF mutation is absent. Using residual nucleic acids from mutation testing, the classifier relied on mRNA levels of MET, TIMP1, TGFA, CITED1, and FN1, and was validated with the TCGA THCA dataset, distinguishing benign from malignant nodules.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/diagnostic-accuracy-in-brafv600e-negative-papillary-thyroid-cancer-via-5-gene-expression-profiling-of-residual-nucleic-acids-from-mutation-testing-a-retrospective-study/345166/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/diagnostic-accuracy-in-brafv600e-negative-papillary-thyroid-cancer-via-5-gene-expression-profiling-of-residual-nucleic-acids-from-mutation-testing-a-retrospective-study/345166.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the goal of the study regarding BRAFV600E-negative PTC?","Question",{"text":112,"@type":113},"To construct an mRNA-based classifier that can identify thyroid cancer in indeterminate nodules even when BRAF mutation is absent.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which genes were used to build the expression-based model?",{"text":117,"@type":113},"The model used the mRNA levels of MET, MET, TIMP1, TGFA, CITED1, and FN1 measured from thyroid specimens.",{"name":119,"@type":110,"acceptedAnswer":120},"How was the model validated?",{"text":121,"@type":113},"Internal dataset results were complemented by external validation using the TCGA THCA dataset.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345166,1790194032,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Wang et al. BMC Cancer (2026) 26:486 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-15818-5](https://doi.org/10.1186/s12885-026-15818-5)  \nRESEARCH Open Access  \nDiagnostic accuracy in BRAFV600Enegative papillary thyroid cancer via 5-gene expression profiling of residual nucleic acids from mutation testing: a retrospective study  \nLiang Wang1†, Wu Mao2†, Hua Deng3, Wei-ping Zhou3, Liang Zhang3* and Jie Li1*  \nAbstract  \nBackground BRAFV600E mutation is insufficient for accurate diagnosis of thyroid neoplasms, although it has been widely used in clinical settings. We aimed to construct a messenger RNA (mRNA)-based model to identify thyroid cancer in indeterminate thyroid nodules in the absence of BRAF mutation.  \nMethods Our cohort consisted of 88 papillary thyroid cancer (PTC) patients with BRAFV600E substitution, 103 BRAF mutation negative PTC cases, and 96 subjects with benign thyroid nodules. Based on the mRNA levels of MET proto-oncogene, receptor tyrosine kinase (MET), TIMP metallopeptidase inhibitor 1 (TIMP1), transforming growth factor alpha (TGFA), Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 1 (CITED1), and fibronectin 1 (FN1) in thyroid specimens, model building was conducted to develop a gene expression-based classifier to differentiate benign from malignant thyroid nodules. In addition, external validation was performed using the thyroid carcinoma (THCA) dataset from the Cancer Genome Atlas (TCGA) .  \nResults Dataset-based bioinformatic analysis confirmed the elevated expression levels of these five genes in PTC compared to normal thyroid tissue. Overall, the binary classified model correctly identified 84 of 88 BRAF-mutated PTCand 75 of 103 BRAF mutation negative PTC as malignant tumors, respectively. For PTC carrying BRAFV600E mutation, the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the curve (AUC) were 0 . 955, 0 . 969, 0 . 966, 0.959 and 0. 987, respectively. More importantly, the diagnostic performance of the approach in determining PTC without BRAF mutation was presented as the sensitivity of 0 . 728, specificity of 0 . 969, PPV of 0 . 962, NPV of 0 . 769, and AUC of 0.871.  \nConclusion We developed and validated a gene expression classifier to assist in the diagnosis of BRAFV600Enegative PTC cases. This tool is poised to become a useful adjunct to individualized management of thyroid cancer in clinical practice.  \n†Liang Wang and Wu Mao contributed equally to this work.  \n*Correspondence:  \nLiang Zhang [zhangliang1999@tsinghua.org.cn](zhangliang1999@tsinghua.org.cn)[ ](zhangliang1999@tsinghua.org.cn)Jie Li  \n[lijiek812@foxmail.com](lijiek812@foxmail.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nWang et al. BMC Cancer (2026) 26:486 Page 2 of 9  \nKeywords ","cbCaie635gfKe1at","https://ap.wps.com/l/cbCaie635gfKe1at","pdf",1560429,"English","# Abstract\n# Introduction\n## Background and clinical challenge\n## Limits of current molecular diagnostics\n## Rationale for gene expression profiling","[{\"question\":\"What was the goal of the study regarding BRAFV600E-negative PTC?\",\"answer\":\"To construct an mRNA-based classifier that can identify thyroid cancer in indeterminate nodules even when BRAF mutation is absent.\"},{\"question\":\"Which genes were used to build the expression-based model?\",\"answer\":\"The model used the mRNA levels of MET, MET, TIMP1, TGFA, CITED1, and FN1 measured from thyroid specimens.\"},{\"question\":\"How was the model validated?\",\"answer\":\"Internal dataset results were complemented by external validation using the TCGA THCA dataset.\"}]","Diagnostic accuracy in BRAFV600E-negative papillary thyroid cancer via 5-gene expression profiling of residual nucleic acids from mutation testing - a retrospective study | PDF",1790056696,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a95aee0ae2c21ebb1a14ada3495cc02.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8af9cc780f7eca17f9884036b704ac4a.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb7a7168372be04ecdb2419719fa250d.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef8db0e103c3c1677fabd2b9b3324fcf.webp",980,1306]